Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS
2020 · Journal of Hepatology · 183 citations
https://doi.org/10.1016/j.jhep.2020.04.024
L
Luis Ibáñez
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
170
Papers
3.3K
Citations
23
h-index
39
i10-index
Luis Ibáñez is an academic researcher from Hospital General Universitario Gregorio Marañón. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation & Hepatitis C virus research. The author has an h-index of 23, co-authored 145 publications.
ORCID: 0000-0002-0309-2727Papers by this author
worksHepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
2024 · Journal of Hepatology · 53 citations
https://doi.org/10.1016/j.jhep.2024.05.033
CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma
2022 · JHEP Reports · 21 citations
https://doi.org/10.1016/j.jhepr.2022.100645
Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis
2024 · Journal of Infection and Public Health · 4 citations
https://doi.org/10.1016/j.jiph.2024.102524
OS-115 Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLD
2024 · Journal of Hepatology · 0 citations
https://doi.org/10.1016/s0168-8278(24)00556-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat